AlcHepNet

AlcHepNet ITAALD Trial | Multi-center clinical study advancing research in severe alcohol-associated hepatitis | Collaborative. Innovative. Patient-focused.

[AlcHepNet @AlcHepNet]

The ITAALD trial is now enrolling patients with sAH.

This multicenter, randomized study evaluates IL-22 (F-652) vs prednisone + integrated AUD therapy (acamprosate + counseling) to improve liver & alcohol-related outcomes.

Learn more https://t.co/URvAxe80S2

[AlcHepNet @AlcHepNet]

New publication out in JHEP Reports from @Bernd_Schnabl and team! 🎉

Peptide YY reduces Candida albicans cytotoxicity in alcohol-associated liver disease—opening new directions for microbiome-targeted therapies. 🔗 https://t.co/0g09PRLkfK

[Thomas G. Cotter, MD MS @TCotterMD]

@AlcHepNet work in @JAMANetworkOpen led by @LaurenNephewMD @nagachalasani

Only 37% of AH pts referred for transplant

Neighborhood disadvantage shapes referral - we’re missing pts before they even reach transplant. Referral is key equity leverage point

https://t.co/r5icpTpCJu

[Doug Simonetto, MD @DougSimonetto]

Excited to share that the ITAALD trial has been officially launched!

This trial is investigating IL-22 followed by AUD tx in severe alcohol-associated hepatitis, building on promising phase 2 results:
https://t.co/K7PKo53PsK

@AlcHepNet @NIAAAnews @Dr_Vijay_Shah @juanpabloarab

[AlcHepNet @AlcHepNet]

ITAALD Study now OPEN for enrollment!

We’re enrolling sAH patients (MELD 20–35). If you have patients who may qualify, we’d love to connect.

Active sites: IU, VCU, UTSW, Cleveland Clinic, Mayo Clinic, University of Louisville.

For more details:
https://t.co/YNOYNALm35

[AlcHepNet @AlcHepNet]

New publication 🚨

“Neighborhood Disadvantage and Access to Liver Transplant Referral for Severe Alcohol-Associated Hepatitis” by @LaurenNephewMD highlights disparities in transplant referral access.

#HealthEquity #Hepatology

[AlcHepNet @AlcHepNet]

@juanpabloarab @ArunJSanyalVCU @nagachalasani @rajVuppaLanchi @DougSimonetto @Dr_Vijay_Shah @singal_ashwani @SamerGawrieh

[AlcHepNet @AlcHepNet]

🚨 New website update!

The AlcHepNet website now has a refreshed design and expanded content. Learn more about our ongoing clinical trial and the investigators advancing alcohol-associated hepatitis research.

Take a look 👇
https://t.co/25a6RnUNdj

#ITAALD #ClinicalTrials

[AlcHepNet @AlcHepNet]

New in @Hepatology: In >218K U.S. patients, AUD pharmacotherapy was linked to fewer hospitalizations and lower alcohol-related costs —greatest savings in advanced liver disease.https://t.co/SsuBPBzU6A

[AlcHepNet @AlcHepNet]

@juanpabloarab @ArunJSanyalVCU @Dr_Vijay_Shah @rajVuppaLanchi @nagachalasani @singal_ashwani

[AlcHepNet @AlcHepNet]

First post + big milestone! 🎉

The ITAALD Trial has officially enrolled its first patient in January. Huge thanks to our investigators and site teams for making this happen.

We’re just getting started. #ITAALD #ClinicalTrials